Humanin: The Neuroprotective Mitochondrial Peptide for Brain Health and Longevity

Disclaimer: This article is for educational purposes only. Humanin is a research peptide — not approved for human use. Consult a qualified healthcare professional before using any peptide compound.

Your mitochondria aren't just power plants. They're signaling hubs — and they speak in peptides.

Humanin is one of those peptides. It's encoded directly in the mitochondrial genome, in the 16S ribosomal RNA region — the same ancient genome that gave us MOTS-c. It was discovered in 2001 by Hashimoto et al. in a screen looking for genes that suppress neuronal death caused by Alzheimer's-associated mutations. The discovery paper appeared in Nature Medicine, and it turned a lot of heads — because Humanin didn't just slow neurodegeneration, it blocked multiple neuronal death pathways simultaneously.

Researchers started calling it the "anti-death peptide." That label stuck.

In the two-plus decades since, Humanin has accrued a research record that stretches from Alzheimer's protection to centenarian longevity genetics to cardiometabolic health. It's one of the most neuroprotective molecules ever identified in the mitochondrial genome — and its levels decline sharply with age, which is part of why longevity researchers keep coming back to it.

Here's what the science actually shows.

What Is Humanin? The Mitochondrial-Derived Peptide Class

Humanin belongs to the mitochondrial-derived peptide (MDP) family — bioactive molecules encoded in the mitochondrial genome rather than nuclear DNA. It's a 21-amino-acid peptide encoded in the 16S rRNA region of the mitochondrial genome, making it a sibling to MOTS-c (encoded in the 12S rRNA region) and the six SHLPs (Small Humanin-Like Peptides, encoded across the 16S rRNA region).

The mitochondrial genome is tiny — only 37 genes, compared to ~20,000 in nuclear DNA. For a long time, biologists assumed it only coded for electron transport chain components and ribosomal machinery. The discovery of Humanin, and later MOTS-c and the SHLPs, revealed something unexpected: the mitochondrial genome encodes a family of signaling peptides that coordinate cellular survival, metabolic adaptation, and stress responses across the whole organism.

Humanin is the most studied MDP. It's detectable in blood, cerebrospinal fluid (CSF), and multiple tissues. Its expression is highest in the brain — which fits its original discovery context — but it circulates systemically and has documented effects in the cardiovascular system, metabolic tissues, and gonads.

Mechanism of Action: How Humanin Protects Neurons

Humanin's neuroprotective potency comes from something unusual: it doesn't rely on a single receptor pathway. It binds and activates three distinct receptor systems, which is part of why it can block so many different cell death triggers simultaneously.

1. The Tripartite Receptor Complex (CNTFR/WSX-1/gp130)

Humanin's primary neuroprotective receptor is a heterotrimer complex formed by three subunits: CNTFR (ciliary neurotrophic factor receptor), WSX-1, and gp130. This is the same gp130 signaling hub used by the IL-6 family of cytokines — and binding this complex activates the JAK/STAT3 pathway.

STAT3 activation is the core of Humanin's neuroprotective and anti-inflammatory signaling:

• Upregulates pro-survival genes in neurons
• Suppresses apoptotic signaling
• Reduces neuroinflammation via downregulation of NF-κB and TNF-α in peripheral tissues
• Supports mitochondrial integrity under oxidative stress

This is why researchers classify Humanin as both a neuroprotective and anti-inflammatory peptide — the STAT3 axis handles both simultaneously.

2. FPRL1/FPR2 (G-Protein Coupled Receptor)

Humanin also binds FPRL1 (formyl peptide receptor-like 1, also called FPR2) — a G-protein coupled receptor expressed on neurons and immune cells. FPR2 signaling contributes to Humanin's anti-inflammatory activity and its ability to modulate microglial activation in the brain, which has implications for neuroinflammatory conditions beyond Alzheimer's.

3. Intracellular Binding: BAX and IGFBP-3

Inside the cell, Humanin binds two key intracellular proteins: BAX and IGFBP-3.

BAX inhibition is the most direct anti-apoptotic mechanism. BAX is a pro-apoptotic protein — it inserts into the mitochondrial outer membrane and triggers cytochrome c release, initiating the mitochondria-mediated apoptosis cascade. Humanin binds directly to BAX and prevents it from activating. This is mitochondria protecting neurons by blocking the very cell death pathway that originates in mitochondria — a piece of elegant biological logic.

IGFBP-3 binding has a different effect. IGFBP-3 (insulin-like growth factor binding protein 3) normally sequesters IGF-1 and blocks its anabolic and pro-survival signaling. Humanin competes with IGF-1 for IGFBP-3 binding, effectively freeing IGF-1 to activate its receptor and potentiate downstream survival and growth signaling. This connects Humanin to the IGF-1 pathway in a way that has implications for longevity — more on that in the centenarian research section.

What Humanin Blocks

Across these three receptor systems, Humanin has demonstrated the ability to block:

• Amyloid-beta toxicity — the core pathological driver of Alzheimer's disease
• NMDA receptor excitotoxicity — the neuronal death mechanism triggered by glutamate overflow, relevant to stroke, TBI, and seizure
• Oxidative stress-induced apoptosis — mitochondrial ROS-driven cell death
• BAX-mediated apoptosis — the direct mitochondrial death pathway
• NF-κB and TNF-α inflammatory signaling — systemic inflammaging

The breadth of that list is what makes Humanin unusual. Most neuroprotective compounds target one pathway. Humanin targets five distinct death mechanisms through its multi-receptor architecture.

Research Highlights

Alzheimer's Protection: The Founding Discovery

The 2001 Hashimoto et al. paper in Nature Medicine established Humanin's identity and kicked off the whole field. The discovery method was a cDNA library screen — researchers were looking for genes that, when overexpressed in cultured neurons, would suppress cell death caused by familial Alzheimer's disease (FAD) mutations.

Humanin was the hit. It suppressed neuronal death from three distinct FAD mutations (familial AD genes) as well as amyloid-beta peptide toxicity. The protection was dose-dependent and robust. Follow-up work confirmed the mechanism: Humanin was blocking the downstream apoptotic cascade at multiple points, not just one.

The Alzheimer's connection is still the most clinically compelling piece of Humanin's research record. The molecule that would become one of the most discussed neuroprotective peptides was identified in a screen designed to find something that could stop Alzheimer's-related neuronal death. That origin story matters.

Centenarian Genetics and Longevity

Cohen et al. published research demonstrating that centenarians and their offspring have significantly higher circulating Humanin levels than age-matched controls. This is one of the most direct links ever established between a mitochondrial-derived peptide and human longevity.

The mechanism isn't fully worked out, but the IGF-1 pathway connection is prominent in this research. Humanin's binding to IGFBP-3 modulates IGF-1 signaling — and the IGF-1 pathway is one of the most conserved longevity regulators across species. In C. elegans, Drosophila, mice, and humans, reduced IGF-1 signaling tends to extend lifespan. Humanin may fine-tune rather than blunt this axis — freeing IGF-1 for tissue protection while also interacting with the pathway's regulatory machinery in ways that favor longevity phenotypes.

The centenarian data suggests this isn't just animal biology. Higher Humanin in long-lived humans is an observational signal worth taking seriously.

Cardiometabolic Effects

Muzumdar et al. (2009) published a key paper showing that systemic Humanin administration in rodents produces significant cardiometabolic benefits:

• Improved insulin sensitivity — consistent with STAT3-mediated anti-inflammatory effects reducing metabolic inflammation
• Reduced atherosclerotic lesions — protective effects on the vasculature
• Cardiac protection from ischemia-reperfusion injury — Humanin-treated hearts showed reduced infarct size and better functional recovery after simulated heart attack conditions

This extended Humanin's profile well beyond neuroprotection. The same peptide that blocks neuronal death also appears to protect the heart and improve metabolic health — fitting for a molecule that activates the gp130/STAT3 axis, which has documented cardioprotective and metabolic effects throughout the body.

Chemotherapy Protection

Guo et al. demonstrated that HNG (Humanin-G, the potent analog — more on this below) protects against cisplatin-induced hearing loss and organ toxicity. Cisplatin is an effective chemotherapy drug with well-documented ototoxicity (hearing loss) as a side effect. HNG showed protective effects on cochlear hair cells, suggesting Humanin's anti-apoptotic machinery can protect against chemo-induced cell death in non-neuronal tissues.

This opens a potential clinical application that's separate from the longevity and cognition angles — chemotherapy adjunct use to protect sensitive tissues from collateral damage.

Age-Related Decline

Humanin levels are measurable in plasma — and they fall with age. Multiple studies report approximately 40% lower circulating Humanin from age 20 to age 70 in humans. This decline correlates inversely with:

• Alzheimer's risk markers
• Visceral fat accumulation
• Insulin resistance
• Inflammatory markers

The fact that Humanin is a circulating signal — not just a local tissue factor — and that it declines with age while protective effects decline in parallel, is why researchers frame it as a "longevity signal." Restoring Humanin levels to youthful ranges is the research hypothesis behind most contemporary peptide work in this space.

Humanin vs. HNG (S14G-Humanin)

Most cutting-edge Humanin research doesn't use native Humanin — it uses HNG, a single amino acid substitution variant where serine at position 14 is replaced with glycine (hence S14G-Humanin, or Humanin-G).

This one substitution makes HNG approximately 1,000x more potent than native Humanin in vitro for neuroprotective endpoints. The substitution stabilizes the peptide's active conformation and improves receptor binding affinity without fundamentally changing its mechanism.

When researchers say "Humanin study," they often mean HNG. When biohackers discuss sourcing, they're usually looking for HNG. The abbreviations are used interchangeably enough that it's worth knowing the distinction.

Humanin Decline With Age: The Longevity Signal

One of the most compelling aspects of Humanin research isn't a specific effect — it's the pattern of decline.

Humanin is detectable in:

• Plasma (most accessible biomarker)
• Cerebrospinal fluid (CSF) — brain-compartment signal
• Testicular tissue — relevant to gonadal aging and male fertility decline
• Other tissues including muscle and liver

The decline from young adulthood to old age is substantial — ~40% by age 70 in plasma measurements from multiple studies. And critically, this decline doesn't happen in isolation. It tracks with:

• Rising Alzheimer's biomarkers (amyloid accumulation, tau pathology)
• Increasing visceral adiposity and metabolic syndrome markers
• Growing insulin resistance
• Elevated inflammatory cytokines
• Cognitive decline markers

Is the Humanin decline causing these changes, or is it a marker of the underlying mitochondrial dysfunction that drives them? Almost certainly both — the mitochondrial-neuronal axis is deeply bidirectional. But the correlation is strong enough, and the mechanism robust enough, that Humanin levels in aging tissue represent a scientifically defensible target for intervention.

This is the framing that drives longevity researcher interest: if you can restore the peptide signal that's been eroding for 50 years, you may be able to restore some of the biological youth that went with it.

Practical Context: Research Use

Humanin (and especially HNG) is a research-stage peptide. It is not approved for human use, not commercially available through mainstream channels, and primarily studied in cell culture and animal models with some observational human data. This section describes what's discussed in research and biohacker communities — not a clinical recommendation.

Routes of Administration

Subcutaneous injection is the systemic route. This delivers Humanin to circulation and achieves measurable plasma levels. It's the most studied administration route for cardiometabolic and anti-aging endpoints.

Intranasal administration is the route most discussed in biohacker communities for cognitive applications. The nose-to-brain pathway allows some peptides to bypass the blood-brain barrier via olfactory and trigeminal nerve transport, achieving higher CNS concentrations than peripheral injection for the same dose. Intranasal is theoretically more direct for neuroprotective applications.

Intracerebroventricular (ICV) injection is used in animal research for direct CNS delivery. This is a research tool, not a human-accessible route.

Research Dose Ranges

Based on animal studies and biohacker community reports (not clinical guidance):

• Subcutaneous: 0.5–2 mg per injection
• Intranasal: 1–5 mg protocols (wide variability in community reports)
• Frequency: typically daily or every other day in research protocols

These ranges vary significantly across studies and community sources. There is no established human dosing protocol.

Sourcing and Availability

Humanin and HNG are considerably harder to source than mainstream peptides like BPC-157 or Ipamorelin. They're not as widely manufactured, and purity verification is even more important than with established peptides. The research peptide supply chain caveats apply — sourcing from vendors who provide third-party assay documentation is non-negotiable.

If you're new to peptide reconstitution, the reconstitution guide covers the basics: supplies, bacteriostatic water, dosing math, and storage.

Stack Context

Humanin's mechanisms complement several other well-researched peptides, making it a natural fit in longevity and cognitive stacks.

Humanin + MOTS-c: The Mitochondrial Duo

This is the most natural pairing in the MDP space. MOTS-c handles the metabolic and peripheral side — AMPK activation, insulin sensitization, muscle metabolic flexibility. Humanin handles the neuronal and central side — neuroprotection, anti-apoptosis, Alzheimer's pathway suppression.

Together, they represent both major mitochondrial-derived peptide axes: metabolic signaling and neuroprotection. Most serious longevity stacks that include one eventually include both. The theoretical rationale is stronger than for almost any other peptide combination — they're literally produced by the same genome, decline in parallel with age, and address complementary but non-overlapping biological targets.

Humanin + Epithalon: Longevity + Neuroprotection

Epithalon activates telomerase — the enzyme that rebuilds telomere caps on chromosomes — and has been studied extensively in Khavinson's Russian research for longevity and age-related disease prevention. Combined with Humanin's neuroprotective and anti-apoptotic mechanisms, the stack covers both telomere biology (upstream of most hallmarks of aging) and active neuronal protection.

Humanin + Semax/Selank: Cognitive Support

Selank and Semax are the two most researched nootropic peptides — both intranasal, both with documented cognitive and anxiolytic effects. Stacking either with intranasal Humanin creates a layered cognitive support protocol: the Russian nootropics handle neurotransmitter modulation and BDNF (brain-derived neurotrophic factor) upregulation, while Humanin provides neuroprotective backbone via BAX inhibition and STAT3 activation.

Humanin + BPC-157: Systemic Protection + Repair

BPC-157 is the most discussed repair peptide in the biohacker space, with documented effects on gut healing, tendon repair, and systemic protection. BPC-157's angiogenic and repair mechanisms are downstream of growth factor signaling. Humanin adds neuroprotective and anti-apoptotic coverage that BPC-157 doesn't specifically address. Combined, they offer complementary systemic protection: BPC-157 for peripheral tissue repair, Humanin for central neuronal and mitochondrial protection.

Ready to build a complete longevity protocol? The Peptide Stacking Guide: Advanced Protocols covers full mitochondrial and longevity stacks with dosing frameworks. — Get the Stacking Guide ($14.99)

Mitochondrial Peptides: How They Compare

Humanin sits in a small but growing class of mitochondrial-derived peptides. Here's how the three best-characterized MDPs compare:

MOTS-c and Humanin are both preclinical/observational — strong mechanistic rationale, solid animal data, growing human observational data, but no randomized clinical trials in humans. SS-31 (Elamipretide) is the most clinically advanced MDP, currently in Phase II/III trials for heart failure and mitochondrial myopathy.

Humanin is the oldest of the three — the original MDP — and arguably still the most neuroprotective molecule in the class.

Why Humanin Matters: The Bottom Line

Humanin's story is compelling for several reasons that don't all apply to most peptides:

1. It was discovered in an Alzheimer's screen — the original research context was preventing neuronal death from the most common neurodegenerative disease. That's not a biohacker origin story; it's a clinical research origin.

2. Multi-receptor, multi-pathway neuroprotection — it doesn't block one death pathway, it blocks five. That's mechanistically unusual and suggests resilience across different neurodegeneration triggers.

3. Centenarian genetics — the association between high Humanin and human longevity is one of the more direct peptide-longevity links in the human data.

4. Age-related decline — it measurably declines with age, in parallel with disease risk. That makes it a logical intervention target rather than just a curiosity.

5. Cardiometabolic benefits — the Muzumdar 2009 data extends Humanin's relevance well beyond pure neuroprotection into metabolic and cardiovascular protection.

The research picture isn't complete — most of the evidence is preclinical, the human data is mostly observational, and there are no RCTs in humans yet. But the mechanistic rationale is stronger for Humanin than for many peptides that get significantly more mainstream attention.

For anyone building a serious longevity or cognitive protection stack, Humanin — and especially HNG — is worth understanding in depth.

Get the Complete Bundle ($19.99) — Beginner's Guide + Stacking Guide together. Everything you need to build a peptide protocol from scratch.

See also: Mitochondrial Peptides: The Complete Guide to MOTS-c, Humanin, and SS-31 — the hub article tying all three mitochondrial peptides together with comparison tables, stack protocols, and clinical evidence.

Disclaimer

This article is for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Humanin is a research peptide — not approved for human use by the FDA or any equivalent regulatory agency. Most evidence is from preclinical (animal and cell culture) studies, with limited observational human data. Consult a qualified healthcare professional before using any peptide compound, particularly if you have neurodegenerative conditions, metabolic disease, cardiovascular disease, or any other health concern. Information in this article is presented in a research and educational context only.